Silver Book Fact

Targeting A-type K+ channels in primary sensory neurons could provide a novel mechanism-based therapy for the treatment of bone cancer pain–one of the most severe types of chronic pain.

Duan, Kai-Zheng, Qian Xu, Xiaho-Meng Zhang, Zhi-Qi Zhao, Yan-Ai Mei, and Yu-Qiu Zhang. Targeting A-Type K+ Channels in Primary Sensory Neurons for Bone Cancer Pain in a Rat Model. Pain. 2012; 153(3): 562-74. http://www.ncbi.nlm.nih.gov/pubmed/22188869

Reference

Title
Targeting A-Type K+ Channels in Primary Sensory Neurons for Bone Cancer Pain in a Rat Model
Publication
Pain
Publication Date
2012
Authors
Duan, Kai-Zheng, Qian Xu, Xiaho-Meng Zhang, Zhi-Qi Zhao, Yan-Ai Mei, and Yu-Qiu Zhang
Volume & Issue
Volume 153, Issue 3
Pages
562-74
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • An opiate agonist often used for persistent pain, tramadol was found in one meta-analysis to significantly reduce neuropathic pain when compared to placebo.  
  • Antiepileptic drugs relieve persistent neuropathic pain. One meta-analysis found gabapentin to be associated with moderate benefit (equivalent to 30% pain relief) in close to 1 in 2 patients, and…  
  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • Researchers have developed several sub-types of ion channels that allow inflammation and growth factors to trigger persistent pain.  
  • Statin use in mouse models show pain-alleviating effects for neuropathic pain.